In8bio Common Stock Shares Outstanding Over Time
| INAB Stock | USD 0.32 0.01 3.03% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out In8bio Performance and In8bio Correlation. In8bio |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of In8bio. If investors know In8bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about In8bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.74) | Return On Assets (0.78) | Return On Equity (1.80) |
The market value of In8bio Inc is measured differently than its book value, which is the value of In8bio that is recorded on the company's balance sheet. Investors also form their own opinion of In8bio's value that differs from its market value or its book value, called intrinsic value, which is In8bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because In8bio's market value can be influenced by many factors that don't directly affect In8bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between In8bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if In8bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, In8bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Common Stock Shares Outstanding Analysis
Compare In8bio Inc and related stocks such as Reviva Pharmaceuticals, Cue Biopharma, and Lantern Pharma Common Stock Shares Outstanding Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RVPH | 2.8 M | 2.8 M | 2.8 M | 2.8 M | 2.8 M | 2.8 M | 2.8 M | 2.8 M | 2.8 M | 2.8 M | 3.1 M | 14.8 M | 19.5 M | 27.9 M | 15 M |
| CUE | 20.6 M | 20.6 M | 20.6 M | 20.6 M | 20.6 M | 20.6 M | 20.6 M | 20.6 M | 20.1 M | 22 M | 28.7 M | 31.3 M | 35.6 M | 45.8 M | 30 M |
| LTRN | 6.2 M | 6.2 M | 6.2 M | 6.2 M | 6.2 M | 6.2 M | 6.2 M | 6.2 M | 6.2 M | 6.3 M | 6.2 M | 10.9 M | 10.9 M | 10.8 M | 9.4 M |
| ANIX | 1.5 M | 8 M | 8.6 M | 9.6 M | 9.6 M | 8.7 M | 12.2 M | 17.6 M | 19.8 M | 22.2 M | 28.6 M | 30.4 M | 31 M | 35.6 M | 37.4 M |
| INMB | 11.2 M | 11.2 M | 11.2 M | 11.2 M | 11.2 M | 11.2 M | 11.2 M | 11.2 M | 11.2 M | 10.3 M | 12 M | 16.1 M | 17.9 M | 18 M | 14.8 M |
| PYPD | 443.2 K | 443.2 K | 443.2 K | 196.2 K | 437.1 K | 437.1 K | 294.1 K | 294.1 K | 443.2 K | 443.2 K | 319.4 K | 624 K | 647.6 K | 1.4 M | 1.5 M |
| ZURA | 17.2 M | 17.2 M | 17.2 M | 17.2 M | 17.2 M | 17.2 M | 17.2 M | 17.2 M | 17.2 M | 17.2 M | 17.2 M | 17.2 M | 17.2 M | 33.1 M | 24.8 M |
| ANNX | 11.5 M | 11.5 M | 11.5 M | 11.5 M | 11.5 M | 11.5 M | 11.5 M | 11.5 M | 11.5 M | 38.2 M | 17 M | 38.3 M | 54.7 M | 75.7 M | 43.1 M |
| WVE | 20.9 M | 20.9 M | 20.9 M | 20.9 M | 20.9 M | 10.5 M | 22.8 M | 26.5 M | 29 M | 33.9 M | 39.2 M | 51.8 M | 78.9 M | 106.1 M | 111.4 M |
| GANX | 5.9 M | 5.9 M | 5.9 M | 5.9 M | 5.9 M | 5.9 M | 5.9 M | 5.9 M | 5.9 M | 11.9 M | 11.9 M | 10.2 M | 11.9 M | 13 M | 11.9 M |
| TFFP | 17.8 M | 17.8 M | 17.8 M | 17.8 M | 17.8 M | 17.8 M | 17.8 M | 17.8 M | 17.8 M | 276.2 K | 817 K | 992.8 K | 1.2 M | 1.8 M | 1.7 M |
| PALI | 1.9 K | 3.7 K | 4.5 K | 5.6 K | 6.7 K | 7 K | 8.3 K | 13.1 K | 15.2 K | 488 | 55.5 K | 12.5 K | 58.7 K | 456 K | 478.8 K |
| ALLR | 113 | 113 | 113 | 113 | 113 | 113 | 113 | 113 | 113 | 113 | 3.89 | 7.57 | 11.34 | 3.3 K | 3.5 K |
| CNSP | 15.7 M | 15.7 M | 15.7 M | 15.7 M | 15.7 M | 15.7 M | 15.7 M | 15.7 M | 439.1 K | 548.3 K | 11.1 M | 17.6 M | 27.2 M | 75.3 K | 71.6 K |
| WINT | 1.0 | 585 | 1 K | 1.3 K | 2 K | 2.3 K | 2.8 K | 6.9 K | 30 K | 218.6 K | 20 K | 30 K | 40 K | 220 K | 231 K |
In8bio Inc and related stocks such as Reviva Pharmaceuticals, Cue Biopharma, and Lantern Pharma Common Stock Shares Outstanding description
The total number of shares of a company's common stock that are currently owned by all its shareholders.My Equities
My Current Equities and Potential Positions
| In8bio Inc | INAB |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | New York; U.S.A |
| Exchange | NASDAQ Exchange |
USD 0.32
Check out In8bio Performance and In8bio Correlation. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
In8bio technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.